RCT of Vonoprazan and high dose Amoxicillin eradication

Recruiting

• Conditions: Helicobacter pylori infection

• Registration Number: jRCTs031200128

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-09-23
• Study Start: 2020-11-04
• Last Update Posted: 2024-10-11

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Patients infected with Helicobacter pylori. Positive patients by Urea breath test, stool Helicobacter pylori antigen test, Helicobacter pylori culture, anti-Helicobacter pylori antibody test (blood), rapid urease test (biopsy sample), or histological diagnosis (biopsy sample) are treat with infected. Patients who give a written informed consent.

Exclusion Criteria

Patients who have Helicobacter pylori eradication history. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Patients with infectious mononucleosis. Patients using atazanavir, rilpivirine, pimozide, ergotamine, suvorexant, lomitapide mesylate, tadalafil, ticagrelor, ibrutinib, asuna previr, ivavradine, venetoclax, lurasidone hydrochloride, anamorelin hydrochloride, finerenone, or isavuconazonium sulfate. Patients using colchicine with liver dysfunction or renal dysfunction. Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. Patients who are disqualified for the study by phyusicians.

Study & Design

• Study Type: Interventional
• Study Design: parallel assignment

Primary Outcome Measures

Name	Time	Method
-		Eradication rate (PPS)